PORTLAND, Ore., May 2, 2016 /PRNewswire-USNewswire/ -- The
Corrona Psoriasis Registry announced it will track the drug safety
reporting for ixekizumab, a new biologic medication by Eli Lilly
and Company (NYSE: LLY) that was recently approved for the
treatment of moderate-to-severe plaque psoriasis. The registry is a
joint collaboration between the National Psoriasis Foundation (NPF)
and Corrona, LLC, the leading sponsor of registries in autoimmune
disease.
The registry will enroll at least 4,000 people with psoriasis on
ixekizumab and follow their treatment for at least eight years.
Over 1,200 people on various psoriasis medications from 100 sites
have joined within the first year of the registry. Registry
participation numbers are expected to grow to more than 10,000
people with moderate-to-severe psoriasis on biologics or systemic
medications and 200 sites. By collecting and analyzing data from
thousands of people over many years, the registry will help
researchers compare the safety and effectiveness of psoriasis
therapies, study other diseases and medical conditions associated
with psoriasis, and better understand the natural course of the
disease.
"This is an exciting time for patients with psoriasis as new
treatments become available, and this registry will provide the
long-term data we need to understand the safety and effectiveness
of these therapies," said Dr. Bruce
Strober, professor and chair of University of Connecticut Health Center Department
of Dermatology and scientific co-director of the registry. "The
information collected will also provide valuable insights into the
relationship between psoriasis and other diseases, as well as the
impact of psoriasis and its treatments on quality of life."
Lilly is the second drug manufacturer to select the Corrona
Psoriasis Registry to meet its regulatory post-approval safety
commitments in psoriasis. "Particularly for newly approved drugs,
these long-term safety studies by an independent organization can
help provide patients, physicians and regulators with the long-term
safety data they need," said Dr. Jeff
Greenberg, chief scientific officer of Corrona.
"Ixekizumab was approved by the FDA based on safety information
drawn from a database of 4,204 patients with moderate-to-severe
plaque psoriasis who volunteered in both controlled and
uncontrolled clinical trials, and physicians are just beginning to
use it in practice," said Nayan
Acharya, M.D., senior medical director, Cardiovascular,
Dermatology and Inflammation, Lilly USA, LLC. "This registry affirms our ongoing
commitment to assess the safety profile of ixekizumab in clinical
practice settings."
Psoriasis is a chronic, immunodysregulatory disease that appears
on the skin. It occurs when the immune system sends out faulty
signals that speed up the growth cycle of skin cells. Psoriasis is
not contagious. As many as 7.5 million Americans have
psoriasis.
About Corrona, LLC
Corrona was founded in 2000 by
leading rheumatologists dedicated to advancing and improving the
care of patients with rheumatic and other autoimmune diseases.
Corrona's mission is to advance medical research and improve the
quality of patient care. Corrona is an independent registry without
any ownership links to the pharmaceutical industry. Learn more at
www.corrona.org.
About the National Psoriasis Foundation
National
Psoriasis Foundation (NPF) is the world's largest nonprofit serving
those with psoriasis and psoriatic arthritis. Our priority is to
provide the information and services people need to take control of
their condition, while increasing research to find a cure. In
addition to serving more than 2.1 million people annually through
our health education and advocacy initiatives, NPF has funded more
than $13 million in psoriatic disease
research grants and fellowships. Learn more about the Psoriasis
Foundation at www.psoriasis.org or call 800-723-9166. Follow us on
Facebook and Twitter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/largest-independent-us-psoriasis-registry-to-track-safety-of-new-biologic-treatment-300260326.html
SOURCE National Psoriasis Foundation